Related Experiment Videos
Conventional therapy and approach to management.
S Vincent Rajkumar1, Robert A Kyle
1Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
Best Practice & Research. Clinical Haematology
|July 20, 2005
Summary
Multiple myeloma (MM) treatment has advanced with new therapies like stem-cell transplants and drugs. This article details a risk-stratified approach for diagnosing and treating MM, focusing on conventional therapies and new agents.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Multiple myeloma (MM) treatment has evolved significantly over the past decade.
- Current therapeutic options include stem-cell transplantation and novel agents like thalidomide and bortezomib.
- Certain patient subsets, particularly those with high-risk MM, have not fully benefited from recent advancements.
Purpose of the Study:
- To outline a comprehensive approach to the diagnosis, risk stratification, and treatment of multiple myeloma.
- To present a risk-based treatment strategy incorporating patient eligibility for stem-cell transplantation.
- To clarify the role and current indications for novel therapeutic agents in MM management.
Main Methods:
- Review of current therapeutic options for multiple myeloma.
- Development of a risk-based diagnostic and treatment algorithm.
- Analysis of the role of novel agents in MM treatment.
Main Results:
- Identification of key therapeutic advancements in multiple myeloma treatment.
- Establishment of a risk-stratified approach for MM management.
- Defined indications for novel agents in specific MM patient populations.
Conclusions:
- A risk-based strategy is crucial for optimizing multiple myeloma treatment.
- Integrating conventional therapies with novel agents and considering transplantation eligibility improves patient outcomes.
- Further research is needed to address treatment challenges in high-risk multiple myeloma patients.